NASDAQ:HZNP

Horizon Therapeutics Public Competitors

$93.54

+9.26 (+10.99 %)

(As of 02/24/2021 01:16 PM ET)

Add

Compare

Today's Range

$85.50

Now: $93.54▼

$94.45

50-Day Range

$71.83

MA: $81.50▼

$91.15

52-Week Range

$23.81

Now: $93.54▼

$91.76

Volume98,567 shs

Average Volume1.97 million shs

Market Capitalization$20.65 billion

P/E Ratio25.56

Dividend YieldN/A

Beta1.15

Horizon Therapeutics Public (NASDAQ:HZNP) Vs. JNJ, LLY, MRK, PFE, ABBV, and BMY

Should you be buying HZNP stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Horizon Therapeutics Public, including Johnson & Johnson (JNJ), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), and Bristol-Myers Squibb (BMY).

Horizon Therapeutics Public vs. Johnson & Johnson Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Johnson & Johnson's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
Johnson & Johnson	21.01%	34.64%	13.40%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Johnson & Johnson, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
Johnson & Johnson	0	3	12	0	2.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Johnson & Johnson has a consensus price target of $178.9333, indicating a potential upside of 9.87%. Given Johnson & Johnson's higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Johnson & Johnson's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
Johnson & Johnson	$82.06 billion	5.23	$15.12 billion	$8.68	18.77

Johnson & Johnson has higher revenue and earnings than Horizon Therapeutics Public. Johnson & Johnson is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Johnson & Johnson on 8 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public vs. Eli Lilly and Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Eli Lilly and's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
Eli Lilly and	24.01%	166.45%	15.18%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Eli Lilly and, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
Eli Lilly and	0	4	10	1	2.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Eli Lilly and has a consensus price target of $192.60, indicating a potential downside of 6.12%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, equities research analysts clearly believe Horizon Therapeutics Public is more favorable than Eli Lilly and.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Eli Lilly and's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
Eli Lilly and	$22.32 billion	8.81	$8.32 billion	$6.04	33.98

Eli Lilly and has higher revenue and earnings than Horizon Therapeutics Public. Eli Lilly and is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Horizon Therapeutics Public on 8 of the 15 factors compared between the two stocks.

Horizon Therapeutics Public vs. Merck & Co., Inc. Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Merck & Co., Inc.'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
Merck & Co., Inc.	24.33%	53.83%	16.83%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Merck & Co., Inc., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
Merck & Co., Inc.	0	2	13	0	2.87

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Merck & Co., Inc. has a consensus price target of $95.3571, indicating a potential upside of 27.26%. Given Merck & Co., Inc.'s higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Merck & Co., Inc.'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
Merck & Co., Inc.	$46.84 billion	4.05	$9.84 billion	$5.19	14.45

Merck & Co., Inc. has higher revenue and earnings than Horizon Therapeutics Public. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Horizon Therapeutics Public vs. Pfizer Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Pfizer's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
Pfizer	17.85%	24.88%	9.32%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Pfizer, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
Pfizer	0	10	5	0	2.33

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Pfizer has a consensus price target of $39.5333, indicating a potential upside of 16.86%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Pfizer's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
Pfizer	$51.75 billion	3.63	$16.27 billion	$2.95	11.46

Pfizer has higher revenue and earnings than Horizon Therapeutics Public. Pfizer is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Pfizer on 10 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public vs. AbbVie Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and AbbVie's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
AbbVie	18.16%	439.24%	13.22%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and AbbVie, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
AbbVie	1	4	14	0	2.68

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. AbbVie has a consensus price target of $114.4118, indicating a potential upside of 5.32%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, equities research analysts clearly believe Horizon Therapeutics Public is more favorable than AbbVie.

Earnings and Valuation

This table compares Horizon Therapeutics Public and AbbVie's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
AbbVie	$33.27 billion	5.77	$7.88 billion	$8.94	12.17

AbbVie has higher revenue and earnings than Horizon Therapeutics Public. AbbVie is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats AbbVie on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public vs. Bristol-Myers Squibb Stock

Horizon Therapeutics Public (NASDAQ:HZNP) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Bristol-Myers Squibb's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	43.55%	25.66%	14.19%
Bristol-Myers Squibb	-0.11%	27.48%	10.77%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Bristol-Myers Squibb, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0	0	8	0	3.00
Bristol-Myers Squibb	0	4	10	1	2.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Bristol-Myers Squibb has a consensus price target of $74.2667, indicating a potential upside of 18.88%. Given Bristol-Myers Squibb's higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Bristol-Myers Squibb's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$1.30 billion	15.95	$573.02 million	$1.94	48.44
Bristol-Myers Squibb	$26.15 billion	5.37	$3.44 billion	$4.69	13.37

Bristol-Myers Squibb has higher revenue and earnings than Horizon Therapeutics Public. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.